Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
The deal is expected to close in the fourth quarter of 2021 and will enable Roche to further expand the portfolio. TIB Molbiol excels in ultra-rapid assay development of emerging infectious diseases
Research collaboration covers multiple antibody research programs
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
